Pulmonx Corporation

LUNG

$2.38

-0.88%

2026-08-31 16:00:00 EDT+$0.00

Healthcare

Medical - Devices

NASDAQ

Active Trading

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. ...

Price Action of LUNG

$2.38

+0.00%+$0.00

High—

Low—

52W High-17.6%

Rel. vol—

Interval

Range5.9h

Volume—SMA5SMA10

—

Pulmonx Corporation is a commercial-stage medical technology company headquartered in Redwood City, California, dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases, particularly severe emphysema. Its flagship product, the Zephyr Endobronchial Valve, is a minimally invasive, one-time procedure performed via bronchoscopy to treat bronchoscopic ...Pulmonx Corporation is a commercial-stage medical technology company headquartered in Redwood City, California, dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases, particularly severe emphysema. Its flagship product, the Zephyr Endobronchial Valve, is a minimally invasive, one-time procedure performed via bronchoscopy to treat bronchoscopic hyperinflation in adults with severe emphysema. The company also offers the Chartis Pulmonary Assessment System, which uses a specialized balloon catheter and console to measure collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that provides quantitative CT analysis for treatment planning. Pulmonx serves patients across the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. With over 40,000 patients treated, the company has established itself as a leader in interventional pulmonology. Financially, Pulmonx generates revenue primarily from the sale of these devices and services, with a gross profit margin of 77.1% but currently operating at a loss due to high R&D and SG&A expenses. The company went public in October 2020 and has a market cap of approximately $95 million. Key leadership includes CEO Glendon E. French, who has over 30 years of experience in medical devices, though recent announcements indicate a transition to Steve Williamson as the new President and CEO. The company continues to invest heavily in research and development to expand its product portfolio and improve patient outcomes, with a focus on innovation and global expansion.ExpandCollapse

Founded

1995

Employees

296

CEO

Glendon E. French

Full Name

Pulmonx Corporation

Sector

Healthcare

Industry

Medical - Devices

ROE

-96.66%

Market Cap

$0.10B

Current Ratio

4.32

WACC

5.75%

ROIC

-49.66%

Contact Information

https://pulmonx.com

650 364 0400

700 Chesapeake Drive, Redwood City, CA 94063

Key Metrics of LUNG

Snapshot

Latest / TTM · 6 periods

Market Cap

$100.52M

ROCE

-49.1%

EV / EBITDA

-2.23x

+0.0% YoY

FCF Yield

-32.1%

+4.5% YoY

Cash Conversion Cycle

264.2d

Current Ratio

4.32

Quick take

TTM —

Positive CCC

Financial Highlights of LUNG

Profitability trend

Latest / TTM · 6 periods

Gross Margin

77.1%

Net Margin

-55.0%

P/E Ratio

-1.97x

n/a

Debt / Equity

1.43

n/a

Current Ratio

4.32

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of LUNG

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.26 · Revenue $21.93M · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.21 · Revenue $25.28M · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.02 · Revenue $90.54M · 4 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.25 · Revenue $23.12M · 1 analysts

Recent history

Aug 4, 2026
Q2 FY2026 · Results reported
EPS $-0.23 · Revenue $22.76M
View filing
May 4, 2026
Q1 FY2026 · Results reported
EPS $-0.33 · Revenue $20.59M
View filing
Mar 10, 2026
FY2025 · Annual results
EPS $-1.33 · Revenue $90.50M
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.34 · Revenue $21.50M
View filing
Aug 1, 2025
Q2 FY2025 · Results reported
EPS $-0.38 · Revenue $23.86M
View filing
May 2, 2025
Q1 FY2025 · Results reported
EPS $-0.36 · Revenue $22.54M
View filing

Financial Statements of LUNG

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$90.5M	+8.0%	+10.5%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-54.0M	+4.2%	+26.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+74.2%	+0.3%	+0.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-59.3%	+13.9%	+36.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-59.7%	+11.3%	+33.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-32.9M	+0.3%	+48.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-36.4%	+7.7%	+53.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	104.2%	+58.3%	+16.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	5.07x	-9.1%	-12.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$129.3M	-20.6%	-4.4%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.33 vs -1.46	+9.1%	-0.23 vs -0.26	+10.4%
Revenue Surprise	$90.5M vs $89.6M	+1.0%	$22.8M vs $21.9M	+3.8%

Insider Transactions of LUNG

Acquisitions (A)

Since Sep 1, 2026

Disposals (D)

Since Sep 1, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	French Glendon E. III	director, officer: President and CEO	Common Stock	D	4,098	$2.26
Sep 1, 2026	French Glendon E. III	director, officer: President and CEO	Common Stock	D	37,784	$2.26
Sep 1, 2026	Radhakrishnan Srikanth	officer: Chief Science & Techn. Officer	Common Stock	D	2,643	$2.26
Sep 1, 2026	Radhakrishnan Srikanth	officer: Chief Science & Techn. Officer	Common Stock	D	2,121	$2.26
Sep 1, 2026	Radhakrishnan Srikanth	officer: Chief Science & Techn. Officer	Common Stock	D	3,618	$2.26

Earnings Call Transcript of LUNG

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx' Second Quarter 2026 Earnings Conference Call. Please be advised that today's conference is being recorded. I would like now to turn the call over to Webb Campbell, Investor Relations. Please go ahead. Webb Campbell: Good afternoon, and thank you for joining today's call. Joining me from Pulmonx are Glen French, President and Chief Executive Officer; and Derrick Sung, Chief Operating Officer and Chief Financial Officer. Earlier today, Pulmonx issued a press release announcing its financial results for the quarter-ended June 30, 2026. A copy of the press release is available on the Pulmonx website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitations, those related to our operating trends, commercial strategies and future financial performance including long-term outlook and full year 2026 guidance, the timing and results of clinical trials, physician engagement, expense management, market opportunity, guidance for revenue, gross margin, operating expense, cash usage, commercial expansion and product demand, adoption and pipeline development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q filed with the SEC on May 4, 2026. Also, during this call, we will discuss certain non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the press release, which is posted on our Investor Relations website. These non-GAAP measures are not intended to be a substitute for our GAAP results. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, July 29, 2026. Pulmonx disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. And with that I will turn the call over to Glen. Glendon French: Thank you, Webb. Good afternoon, everyone, and …

Leadership Team of LUNG

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Geoffrey Beran Rose	Chief Commercial Officer	USD 632,293	Male	1974	Active
David A. Lehman	General Counsel & Secretary	USD 516,643	Male	1961	Active
Glendon E. French	Chief Executive Officer, President & Director	USD 319,520	Male	1962	Active
Derrick Sung	Chief Financial Officer & Chief Operating Officer	USD 283,391	—	1973	Active
Srikanth Radhakrishnan	Chief Science & Technology Officer	—	Male	1973	Active
Marcee Maroney	Vice President of Marketing	—	Female	1970	Active
Narinder S. Shargill	Senior Vice President of Global Medical & Clinical Affairs	—	—	1955	Active
Jérôme Erath	Senior Vice President & GM of International	—	Male	—	Active
John McKune	VP of Finance & Corporate Controller	—	Male	1976	Active
Lisa Paul	Chief People Officer	—	Female	1964	Active

Recent News of LUNG

Zacks Investment Research8/3/2026Neutral

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha7/30/2026Neutral

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

MarketBeat7/29/2026Neutral

Pulmonx Q2 Earnings Call Highlights

Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China.

Zacks Investment Research7/29/2026Neutral

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.38 per share a year ago.

GlobeNewsWire7/29/2026Neutral

Pulmonx Reports Second Quarter 2026 Financial Results

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.

Historical Employee Count of LUNG

Current

296

Change

+1.72%

Minimum

253

Maximum

296

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	296	10-K	Mar 10, 2026	View
Dec 31, 2024	291	10-K	Feb 25, 2025	View
Dec 31, 2023	279	10-K	Feb 27, 2024	View
Dec 31, 2022	269	10-K	Mar 1, 2023	View
Dec 31, 2021	253	10-K	Mar 1, 2022	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Pulmonx Corporation